Mark Dybul - 13 Feb 2024 Form 4 Insider Report for RENOVARO BIOSCIENCES INC. (RENB)

Role
Chief Executive Officer, Director
Signature
/s/ Mark Dybul
Issuer symbol
RENB
Transactions as of
13 Feb 2024
Transactions value $
$0
Form type
4
Date filed
16 Feb 2024, 09:06
Previous filing
15 Sep 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RENB Option to Purchase Common Stock Disposed to Issuer -7.56K -100% 0 13 Feb 2024 Common Stock 7.56K $5.95 Direct F1, F2
transaction RENB Option to Purchase Common Stock Award +7.56K 7.56K 13 Feb 2024 Common Stock 7.56K $1.92 Direct F2
transaction RENB Option to Purchase Common Stock Disposed to Issuer -5.23K -100% 0 13 Feb 2024 Common Stock 5.23K $5.74 Direct F2
transaction RENB Option to Purchase Common Stock Award +5.23K 5.23K 13 Feb 2024 Common Stock 5.23K $1.92 Direct F2
transaction RENB Option to Purchase Common Stock Disposed to Issuer -300K -100% 0 13 Feb 2024 Common Stock 300K $6.50 Direct F2
transaction RENB Option to Purchase Common Stock Award +300K 300K 13 Feb 2024 Common Stock 300K $1.92 Direct F2
transaction RENB Option to Purchase Common Stock Disposed to Issuer -450K -100% 0 13 Feb 2024 Common Stock 450K $8.00 Direct F2
transaction RENB Option to Purchase Common Stock Award +450K 450K 13 Feb 2024 Common Stock 450K $1.92 Direct F2
transaction RENB Option to Purchase Common Stock Disposed to Issuer -2M -100% 0 13 Feb 2024 Common Stock 2M $4.57 Direct F2, F3
transaction RENB Option to Purchase Common Stock Award +2M 2M 13 Feb 2024 Common Stock 2M $1.92 Direct F2, F3
transaction RENB Option to Purchase Common Stock Disposed to Issuer -350K -100% 0 13 Feb 2024 Common Stock 350K $2.54 Direct F2, F4
transaction RENB Option to Purchase Common Stock Award +350K 350K 13 Feb 2024 Common Stock 350K $1.92 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vested in three equal installments on February 28, 2019, February 28, 2020 and February 28, 2021.
F2 The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options.
F3 The option vested in two equal installments on July 1, 2022 and July 1, 2023. The remainder of the option vests on July 1, 2024.
F4 One third of the option vested on August 25, 2023. The remainder of the option shall vest in two equal installments on August 25, 2024 and August 25, 2025.